Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00332436 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension
A Phase 3 study of Ocular Hypertension, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 586
- Enrollment target
- 1
- Study location
NCT00332436: Completed Phase 3 study of Ocular Hypertension, sponsored by Allergan.
NCT00332436 is a Phase 3 study of Ocular Hypertension that has completed, run by Allergan. The registered enrollment target is 586 participants, above the 267-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (119% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00332436, a Phase 3 study of Ocular Hypertension, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 586 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the safety and efficacy of Brimonidine/Timolol Fixed Combination in patients with glaucoma or ocular hypertension
Conditions Studied
Interventions
- DRUG brimonidine/timolol fixed combination
Study Locations (1)
Kentucky
- - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 586 participants |
| Start Date | 1999-12 |
| Est. Completion | 2001-11 |
| Phase | Phase 3 |
What the finished NCT00332436 record still lists
NCT00332436 is an interventional study that assigns participants to a tested intervention. The registered 586 participants enrollment target is mid-sized for trials with a published cap, above the 267-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (119% higher).
The record links to 1 condition, with Ocular Hypertension appearing as the primary indexed condition, and to 1 intervention - of which brimonidine/timolol fixed combination is the first listed.
NCT00332436 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT00332436 about?
NCT00332436 is a clinical study titled "Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension". The purpose of this study is to assess the safety and efficacy of Brimonidine/Timolol Fixed Combination in patients with glaucoma or ocular hypertension
What is the current status of trial NCT00332436?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 586 participants. The study started on 1999-12. Estimated completion is 2001-11.
What conditions does trial NCT00332436 study?
This clinical trial studies the following conditions: Ocular Hypertension.
What interventions are being tested in trial NCT00332436?
The interventions under investigation include: brimonidine/timolol fixed combination (DRUG).
Who is sponsoring clinical trial NCT00332436?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00332436 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00332436's enrollment target sits among peer trials
586 9th of 54 higher than 46 of 54 other Ocular Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ocular Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
RECRUITING · Phase 3
-
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
ACTIVE NOT RECRUITING · Phase 3
-
Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04134260 · 586 participants · Phase 3
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
- NCT06100770 · 586 participants
Aveir AR Coverage With Evidence Development (CED) Study
- NCT06183281 · 586 participants · NA
Integrating Nonpharmacologic Strategies for Pain With Inclusion, Respect, and Equity
- NCT06976203 · 586 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia